ABBV

Deeply Undervalued, Income Generating (5.8% Yield), Blue Chip Opportunity

This biopharmaceutical company is engaged in research, development and marketing of biotech drugs. In this article, we analyze its business mix, growth and income prospects, balance sheet, risks and finally conclude with our opinion on whether the company’s stock offers an attractive balance between risks and rewards.